Records 181–220 of 290. Open a study to inspect the full evidence record. Source links lead directly to the publication. Updated 19 October 2026.
Exercise and recovery (15) · Forms, absorption and food sources (6) · Skin and topical formulations (1) · Safety, interactions and special populations (4) · Cardiovascular and metabolic health (7) · Bone and joint health (1) · Allergies, histamine and mast cells (1) · Brain, cognition and sleep (2) · Liver and metabolic health (2) · Immunity and respiratory health (1)
Meta-analysis of placebo-controlled exercise studies. Pooled performance and oxygen-uptake changes were small; the authors judged the likely practical effect trivial.
Randomized double-blind placebo-controlled four-arm athlete trial. Selected body-composition and metabolic measures increased within the quercetin arm; oxygen-uptake changes were not significant.
Randomized double-blind placebo-controlled badminton trial. Time to exhaustion increased within the quercetin group, but oxygen uptake, lactate, and body-fat measures did not differ clearly.
Randomized double-blind placebo-controlled four-arm athlete trial. The abstract reports a within-group LDL decrease with the combination, without a clear between-group lipid benefit.
Randomized double-blind placebo-controlled crossover exercise study. The combination blunted the exercise-related rise in F2-isoprostanes but did not improve several other oxidation or inflammatory markers.
Randomized double-blind placebo-controlled runner trial. A lipid-peroxidation marker decreased, but running performance, oxygen uptake, and other antioxidant measures did not improve.
Double-blind placebo-controlled crossover performance trial. Oxygen uptake, loaded-march responses, cycling time-trial performance, and perceived exertion did not improve.
Randomized double-blind placebo-controlled eccentric-exercise trial. Quercetin did not improve strength loss, soreness, swelling, creatine kinase, or measured inflammatory responses.
Randomized double-blind placebo-controlled four-arm athlete trial. Between-group differences in exhaustion time, muscle-damage indices, and body fat were not significant.
Randomized double-blind placebo-controlled four-arm athlete biomarker trial. Selected inflammatory and oxidative measures favored the combination, while several comparisons were only marginally significant.
Placebo-controlled crossover repeated-sprint study. Sprint performance and inflammatory or xanthine-oxidase responses did not improve; one fatigue-decrement measure was worse with quercetin.
Systematic review and meta-analysis of human exercise studies. A pooled endurance effect favored quercetin but was between trivial and small.
Randomized placebo-controlled crossover exercise trial. Plasma quercetin rose strongly, but inflammatory and immune responses did not differ from placebo.
Randomized placebo-controlled crossover exercise trial. A treadmill time trial improved modestly with quercetin; mitochondrial DNA and related gene-expression changes were not statistically significant.
Randomized double-blind placebo-controlled crossover exercise trial. Maximal oxygen uptake and related physiological measures did not improve.
Randomized double-blind placebo-controlled metabolomics study. Supplementation altered circulating quercetin conjugates and selected metabolite profiles, particularly at the higher dose; inflammatory and oxidative metabolite measures were not improved.
Randomized crossover absorption study. The highest-fat breakfast increased peak quercetin concentration by about 45% and exposure by about 32% relative to the fat-free meal.
Narrative review of quercetin delivery approaches. Experimental delivery systems could improve solubility and measured exposure.
Randomized single-blind diet-controlled crossover absorption study. The tested bar produced substantially higher plasma exposure than the tested capsule.
Human food-matrix pharmacokinetic comparison. Onion powder produced greater and earlier plasma quercetin exposure than apple peel powder; the mixture gave intermediate results.
Human parallel-group formulation pharmacokinetic comparison. Peak concentrations differed numerically across carriers, but absorption differences were not statistically significant because of substantial variation.
Comparative in vivo human skin penetration study. Colloidal silica increased quercetin uptake into skin; other tested formulation changes did not show significant improvements.
Randomized open-label two-period crossover interaction study. Quercetin reduced talinolol exposure and peak concentration, with differences by MDR1 genotype.
Randomized open-label two-period crossover interaction study. Midazolam exposure decreased in selected CYP3A5 genotype groups, consistent with increased probe-drug metabolism under this schedule.
Placebo-controlled human pharmacokinetic study with cell-transport experiments. Pravastatin exposure and peak concentration increased by approximately 24% and 31%; cell experiments supported OATP1B1 inhibition.
Rat pharmacokinetic study with supporting cell and enzyme assays. Quercetin increased oral doxorubicin exposure in rats but did not alter intravenous exposure under the tested conditions.
Randomized double-blind placebo-controlled trial. Systolic pressure fell more with quercetin than placebo. Between-group differences in diastolic pressure, lipids, and measured inflammatory markers were not significant.
Narrative review of blood-pressure evidence and mechanisms. The review describes blood-pressure reductions in some hypertensive studies and several proposed vascular mechanisms.
Reported double-blind randomized dyslipidemia trial. The abstract reports improved lipid values in the intervention group.
Double-blind placebo-controlled crossover acute blood-pressure study. Blood pressure decreased in the hypertensive group but not the normotensive comparison; ACE activity, endothelin/nitric oxide measures, and flow-mediated dilation did not explain the effect.
Randomized placebo-controlled community trial. Plasma quercetin increased, but overall effects on inflammatory, lipid, blood-pressure, and other disease-risk markers were small or negligible.
Randomized double-blind placebo-controlled parallel trial. Selected lipid, glucose, and pressure measures improved, while IL-6 and soluble VCAM-1 did not.
Retrospective APOE subgroup analysis of a randomized double-blind crossover trial. Pressure and lipid responses differed by genotype; APOE4 carriers had reductions in HDL and apoA1 and an increased LDL-to-HDL ratio.
Randomized double-blind placebo-controlled trial. The combination improved selected symptom and function scores. A cartilage biomarker result was a trend rather than definitive evidence of structural benefit.
Laboratory mast-cell experiments plus two open-label human skin pilots. Quercetin inhibited selected mast-cell responses in culture and reduced skin responses in the small uncontrolled pilots.
Randomized placebo-controlled community cognition trial. Memory, attention, reaction time, psychomotor speed, and cognitive flexibility did not improve despite higher plasma quercetin.
Randomized double-blind placebo-controlled military-training trial. Energy, fatigue, and sleep quality did not improve relative to placebo.
Randomized double-blind placebo-controlled crossover calorimetry pilot. Resting energy expenditure and respiratory quotient were not improved relative to placebo.
Randomized double-blind placebo-controlled body-composition analysis. Body mass and composition did not improve, including among participants with overweight or obesity.
Double-blind placebo-controlled acute sarcoidosis study. Selected blood oxidative-stress and inflammatory markers decreased after quercetin.
Design tiers organize different kinds of evidence; read the source-specific limitations before applying a result. The full library is curated by Biohack Blueprint. Each evidence record lists its editorial author and reviewers.
